Instil Bio Inc. - Asset Resilience Ratio
Instil Bio Inc. (TIL) has an Asset Resilience Ratio of 34.70% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Instil Bio Inc. to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Instil Bio Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Instil Bio Inc. balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Instil Bio Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore TIL long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $69.55 Million | 34.7% |
| Total Liquid Assets | $69.55 Million | 34.70% |
Asset Resilience Insights
- Very High Liquidity: Instil Bio Inc. maintains exceptional liquid asset reserves at 34.70% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Instil Bio Inc. Industry Peers by Asset Resilience Ratio
Compare Instil Bio Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Instil Bio Inc. (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Instil Bio Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 34.14% | $69.49 Million | $203.52 Million | -5.51pp |
| 2024-12-31 | 39.65% | $104.51 Million | $263.57 Million | -3.70pp |
| 2023-12-31 | 43.35% | $141.16 Million | $325.63 Million | -1.70pp |
| 2022-12-31 | 45.05% | $217.20 Million | $482.13 Million | -23.23pp |
| 2021-12-31 | 68.28% | $416.51 Million | $609.98 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $319.01 Million | -- |
About Instil Bio Inc.
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.